RSS   Newsletter   Contact   Advertise with us

Bristol-Myers Squibb completes divestment of manufacturing facility in Anagni, Italy

Christian Fernsby ▼ | January 7, 2020
Bristol-Myers Squibb Company announced today that it has completed its previously announced divestment of its oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy, to Catalent Inc.
Bristol-Myers Squibb
Acquisition   Bristol-Myers Squibb
The divestiture is part of Bristol-Myers Squibb’s strategy to simplify and to realign its business portfolio to address changes in its business and the future requirements of its evolving pipeline.

Topics: Bristol-Myers Squibb divest manufacturing facility Italy

The Anagni facility manufactures and packages cardiovascular, anticancer, metabolic and anti-inflammatory medicines as well as non-penicillin-based antibiotics, antivirals, analgesics as injectables and biologics. The Company is focusing resources on its highest priorities of discovering, developing and delivering transformational medicines for patients facing serious diseases.


 

MORE INSIDE POST